HUP1000243A2 - 8-hidroxy-quinoline derivatives - Google Patents

8-hidroxy-quinoline derivatives

Info

Publication number
HUP1000243A2
HUP1000243A2 HU1000243A HUP1000243A HUP1000243A2 HU P1000243 A2 HUP1000243 A2 HU P1000243A2 HU 1000243 A HU1000243 A HU 1000243A HU P1000243 A HUP1000243 A HU P1000243A HU P1000243 A2 HUP1000243 A2 HU P1000243A2
Authority
HU
Hungary
Prior art keywords
hidroxy
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
HU1000243A
Other languages
English (en)
Hungarian (hu)
Inventor
Laszlo Dr Puskas
Csaba Dr Szabo
Ivan Dr Kanizsai
Mario Gyuris
Ramona Madacsi
Bela Dr Ozsvari
Liliana Dr Feher
Gabor Dr Tamas
Original Assignee
Avidin Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidin Kft filed Critical Avidin Kft
Priority to HU1000243A priority Critical patent/HUP1000243A2/hu
Publication of HU1000243D0 publication Critical patent/HU1000243D0/hu
Priority to PCT/HU2011/000043 priority patent/WO2011148208A1/en
Priority to EA201270787A priority patent/EA021026B1/ru
Priority to HUE11752335A priority patent/HUE050886T2/hu
Priority to CN201180033524.5A priority patent/CN102985407B/zh
Priority to DK11752335.7T priority patent/DK2566849T3/da
Priority to JP2013508559A priority patent/JP5812541B2/ja
Priority to US13/696,541 priority patent/US8871937B2/en
Priority to PL11752335T priority patent/PL2566849T3/pl
Priority to AU2011256989A priority patent/AU2011256989B2/en
Priority to RS20191622A priority patent/RS59678B1/sr
Priority to MX2012012883A priority patent/MX337999B/es
Priority to NZ603967A priority patent/NZ603967A/en
Priority to EP11752335.7A priority patent/EP2566849B1/en
Priority to CA2798419A priority patent/CA2798419C/en
Priority to SI201131826T priority patent/SI2566849T1/sl
Priority to HRP20192278TT priority patent/HRP20192278T1/hr
Priority to SM20190710T priority patent/SMT201900710T1/it
Priority to PT117523357T priority patent/PT2566849T/pt
Priority to ES11752335T priority patent/ES2761832T3/es
Priority to KR1020127030702A priority patent/KR101837974B1/ko
Publication of HUP1000243A2 publication Critical patent/HUP1000243A2/hu
Priority to CY20191101327T priority patent/CY1122426T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HU1000243A 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives HUP1000243A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
KR1020127030702A KR101837974B1 (ko) 2010-05-06 2011-05-06 8-하이드록시-퀴놀린 유도체
RS20191622A RS59678B1 (sr) 2010-05-06 2011-05-06 Derivati 8-hidroksi-hinolina
NZ603967A NZ603967A (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
HUE11752335A HUE050886T2 (hu) 2010-05-06 2011-05-06 8-hidroxi-kinolin származékok
CN201180033524.5A CN102985407B (zh) 2010-05-06 2011-05-06 8-羟基-喹啉衍生物
DK11752335.7T DK2566849T3 (da) 2010-05-06 2011-05-06 8-Hydroxy-quinolinderivater
JP2013508559A JP5812541B2 (ja) 2010-05-06 2011-05-06 ８−ヒドロキシキノリン誘導体
US13/696,541 US8871937B2 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
PL11752335T PL2566849T3 (pl) 2010-05-06 2011-05-06 Pochodne 8-hydroksychinoliny
AU2011256989A AU2011256989B2 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
MX2012012883A MX337999B (es) 2010-05-06 2011-05-06 Derivados de 8-hidroxiquinolina.
EA201270787A EA021026B1 (ru) 2010-05-06 2011-05-06 8-гидроксихинолиновые производные
EP11752335.7A EP2566849B1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
CA2798419A CA2798419C (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives
SI201131826T SI2566849T1 (sl) 2010-05-06 2011-05-06 Derivati 8-hidroksi-kinolina
HRP20192278TT HRP20192278T1 (hr) 2010-05-06 2011-05-06 Derivati 8-hidroksi-kinolina
SM20190710T SMT201900710T1 (it) 2010-05-06 2011-05-06 Derivati di 8-idrossi-chinolina
PT117523357T PT2566849T (pt) 2010-05-06 2011-05-06 Derivados de 8-hidroxiquinolina
ES11752335T ES2761832T3 (es) 2010-05-06 2011-05-06 Derivados de la 8-hidroxiquinolina
CY20191101327T CY1122426T1 (el) 2010-05-06 2019-12-17 Παραγωγα 8-υδροξυ-κινολινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives

Publications (2)

Publication Number Publication Date
HU1000243D0 HU1000243D0 (en) 2010-06-28
HUP1000243A2 true HUP1000243A2 (en) 2012-01-30

Family

ID=89989711

Family Applications (2)

Application Number Title Priority Date Filing Date
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
HUE11752335A HUE050886T2 (hu) 2010-05-06 2011-05-06 8-hidroxi-kinolin származékok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE11752335A HUE050886T2 (hu) 2010-05-06 2011-05-06 8-hidroxi-kinolin származékok

Country Status (21)

Country Link
US (1) US8871937B2 (OSRAM)
EP (1) EP2566849B1 (OSRAM)
JP (1) JP5812541B2 (OSRAM)
KR (1) KR101837974B1 (OSRAM)
CN (1) CN102985407B (OSRAM)
AU (1) AU2011256989B2 (OSRAM)
CA (1) CA2798419C (OSRAM)
CY (1) CY1122426T1 (OSRAM)
DK (1) DK2566849T3 (OSRAM)
EA (1) EA021026B1 (OSRAM)
ES (1) ES2761832T3 (OSRAM)
HR (1) HRP20192278T1 (OSRAM)
HU (2) HUP1000243A2 (OSRAM)
MX (1) MX337999B (OSRAM)
NZ (1) NZ603967A (OSRAM)
PL (1) PL2566849T3 (OSRAM)
PT (1) PT2566849T (OSRAM)
RS (1) RS59678B1 (OSRAM)
SI (1) SI2566849T1 (OSRAM)
SM (1) SMT201900710T1 (OSRAM)
WO (1) WO2011148208A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) * 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
US10624881B2 (en) * 2015-10-12 2020-04-21 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
BR0013666A (pt) 1999-08-27 2002-05-14 Cytovia Inc "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
WO2002030411A2 (en) 2000-10-13 2002-04-18 Johns Hopkins University Treatment of apoptotic cell death
US6552076B2 (en) 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
DE60233738D1 (de) 2001-07-10 2009-10-29 Biogen Idec Inc Hemmung des apoptoseprozesses und verbesserung der zelleistung
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
CA2475963A1 (en) 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004242947B2 (en) 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1966157B1 (en) 2005-11-15 2010-03-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
WO2008014602A1 (en) * 2006-07-25 2008-02-07 Envivo Pharmaceuticals, Inc. Quinoline derivatives
EP3085367A3 (en) * 2007-03-20 2017-01-25 Brandeis University Compositions for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
JP2010530736A (ja) 2007-05-25 2010-09-16 バーンハム インスティトゥート フォー メディカル リサーチ タプシガルジンにより誘導される細胞死の阻害剤
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
WO2009151972A1 (en) * 2008-05-28 2009-12-17 , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command Small molecule inhibitors of botulinum neurotoxins
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
CA2786289A1 (en) * 2010-01-06 2011-07-14 Joseph P. Errico Methods and compositions of targeted drug development

Also Published As

Publication number Publication date
PL2566849T3 (pl) 2020-03-31
EP2566849A1 (en) 2013-03-13
SMT201900710T1 (it) 2020-01-14
US20130131096A1 (en) 2013-05-23
CN102985407A (zh) 2013-03-20
NZ603967A (en) 2014-06-27
EA201270787A1 (ru) 2013-04-30
RS59678B1 (sr) 2020-01-31
KR20130029772A (ko) 2013-03-25
AU2011256989A1 (en) 2013-01-10
CA2798419C (en) 2021-01-05
JP2013525473A (ja) 2013-06-20
US8871937B2 (en) 2014-10-28
KR101837974B1 (ko) 2018-03-13
CY1122426T1 (el) 2021-01-27
AU2011256989B2 (en) 2014-08-21
WO2011148208A1 (en) 2011-12-01
CA2798419A1 (en) 2011-12-01
HUE050886T2 (hu) 2021-01-28
JP5812541B2 (ja) 2015-11-17
ES2761832T3 (es) 2020-05-21
MX337999B (es) 2016-03-30
PT2566849T (pt) 2020-01-06
HU1000243D0 (en) 2010-06-28
DK2566849T3 (da) 2020-01-02
SI2566849T1 (sl) 2020-02-28
EA021026B1 (ru) 2015-03-31
EP2566849B1 (en) 2019-09-18
CN102985407B (zh) 2015-09-09
HRP20192278T1 (hr) 2020-03-06
MX2012012883A (es) 2013-03-20

Similar Documents

Publication Publication Date Title
IL222646A0 (en) N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
DK3342786T3 (en) Anti-dll3-antistof
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
EP2566479A4 (en) AZA-INDAZOLES
AP2012006360A0 (en) 5-Alkynyl-pyrimidines
EP2640189A4 (en) 3-deutero-pomalidomide
ZA201300032B (en) Tetrahydrocarboline derivative
EP2641891A4 (en) PKC ACTIVATOR-
GB2490849B (en) Di-aspirin derivatives
ZA201303887B (en) 2-carboxamide-4-piperazinyl-benzofuran derivative
PT2628733E (pt) Derivado de acilbenzeno
HU1000243D0 (en) 8-hidroxy-quinoline derivatives
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
AU4937P (en) FlatinsulGL Myoporum insulare
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
GB201001102D0 (en) Uni-barrow
GB201000246D0 (en) Head-kase
GB201000020D0 (en) Velcrose
GB201000802D0 (en) Gloyster
GB201000066D0 (en) 1Velcrose
GB201000166D0 (en) Doordeadman
GB201000203D0 (en) Formits
AU2010194V (en) CalpenGL Calothamnus quadrifidus

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished